Katholisches Klinikum Bochum gGmbH

The department focuses on advancing diagnostic imaging and laboratory methods to improve early detection of complex diseases. Research aims to validate novel biomarkers and refine procedural tools that support patient‑centered care.

• Development of high‑resolution imaging for tumor staging
• Evaluation of blood‑based biomarkers for immune disorders
• Integration of digital pathology in routine diagnostics
• Optimization of minimally invasive biopsy techniques

Katholisches Klinikum Bochum gGmbH contributes to 72 trials with 45 investigators, emphasizing innovative diagnostic solutions across therapeutic areas.

Clinical studies target conditions such as heart failure with preserved ejection fraction and related metabolic liver disease. Trials assess new therapeutic strategies to improve cardiac function and patient outcomes.

• Assessment of novel agents for HFpEF management
• Exploration of metabolic interventions in cardiac patients
• Long‑term safety monitoring of cardiovascular therapies
• Impact of lifestyle modification programs on disease progression

The site’s cardiovascular program leverages a multidisciplinary team to enroll patients in cutting‑edge investigations.

Research includes rare genetic disorders affecting infants and young adults, with a focus on early diagnosis and disease‑modifying treatments. Studies aim to translate genetic insights into clinical benefit.

• Screening programs for hereditary metabolic syndromes
• Gene‑therapy feasibility studies in neonatal cohorts
• Evaluation of biomarkers for early disease detection
• Longitudinal follow‑up of congenital cardiac anomalies

Collaborative efforts at the Bochum hospital enhance access to specialized care for these vulnerable populations.

The institution conducts trials on gastrointestinal cancers and inflammatory conditions, including colorectal, gastric, and pancreatic cancers. Objectives center on improving survival and quality of life through innovative therapies.

• Adjuvant treatment strategies after colorectal resection
• Combination immunotherapy for advanced gastric cancer
• Targeted agents for metastatic pancreatic ductal adenocarcinoma
• Evaluation of enzyme replacement in postoperative pancreatic insufficiency

With a strong oncology focus, the site supports over 70 active trials addressing digestive system malignancies.

Studies explore autoimmune and inflammatory disorders such as myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, and hidradenitis suppurativa. The goal is to test novel immunomodulators and improve disease control.

• Phase studies of anti‑FcRn antibodies in generalized myasthenia gravis
• Safety and efficacy of targeted therapies for CIDP
• Long‑term outcomes of IL‑17 inhibition in hidradenitis suppurativa
• Biomarker analysis for treatment response in autoimmune neuropathies

The department’s expertise in immunology supports a robust pipeline of trials for rare and common immune conditions.

A broad portfolio addresses solid tumors, including melanoma, lung, colorectal, and breast cancers. Research seeks to evaluate new targeted agents, immunotherapies, and combination regimens to extend patient survival.

• Comparative studies of anti‑EGFR versus anti‑VEGF combinations in colorectal cancer
• Peri‑operative immunotherapy for resectable melanoma
• Combination checkpoint inhibition in non‑small cell lung cancer
• Biomarker‑driven trials for KRAS‑mutated colorectal adenocarcinoma

Katholisches Klinikum Bochum gGmbH is a leading site for oncology trials, contributing to the national network of cancer research.

Clinical investigations target neurodegenerative and demyelinating disorders, including multiple sclerosis, Parkinson’s disease, and Huntington’s disease. Efforts aim to halt disease progression and improve neurological function.

• Evaluation of B‑cell depletion strategies in pediatric multiple sclerosis
• Antisense oligonucleotide therapy for early Huntington’s disease
• Neuroprotective agents for Parkinson’s disease progression
• Long‑term safety of disease‑modifying therapies in relapsing MS

The neurology program integrates advanced imaging and biomarker assessments to support trial endpoints.

Research includes metabolic liver disease, diabetes, and related metabolic dysfunctions, with a focus on optimizing postprandial glucose control and addressing metabolic complications of cancer.

• Rapid‑acting insulin formulations for type 1 diabetes
• Impact of metabolic dysfunction on outcomes in heart failure
• Evaluation of nutritional interventions in patients with MASLD
• Pharmacokinetic studies of metabolic enzymes in oncology patients

Multidisciplinary collaboration ensures comprehensive metabolic monitoring across trial participants.

Trials address chronic lung conditions such as bronchiectasis and non‑small cell lung cancer, focusing on therapeutic efficacy and quality of life improvements.

• Targeted therapy evaluation in advanced NSCLC
• Antibiotic stewardship in bronchiectasis management
• Inhaled anti‑inflammatory agents for chronic respiratory disease
• Patient‑reported outcome measures in lung disease trials

The site’s pulmonology unit provides specialized care for respiratory research participants.

Investigations include chronic skin disorders such as hidradenitis suppurativa, prurigo nodularis, and chronic spontaneous urticaria. Studies evaluate novel biologics and safety of long‑term treatment.

• IL‑17 inhibition for moderate to severe hidradenitis suppurativa
• Topical agents for actinic keratosis prevention
• Biologic therapies for chronic spontaneous urticaria
• Quality‑of‑life assessments in prurigo nodularis trials

Dermatology expertise at the Bochum clinic supports robust enrollment and follow‑up for skin disease trials.

A subset of studies spans multiple domains, focusing on overarching goals such as enhancing patient safety, improving diagnostic accuracy, and validating new therapeutic concepts.

• Cross‑disciplinary safety monitoring across trial phases
• Implementation of electronic data capture for trial efficiency
• Patient education initiatives to boost trial awareness
• Health‑economic analyses of emerging treatments

The hospital’s integrated research infrastructure enables flexible support for diverse clinical investigations.